CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 9 enrolled
Drug / intervention
SHR3680 +1 moredrug
Likely dose
SHR3680 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03741712
NCT03741712Phase 2Terminated
Terminated
CompareCT.gov

A Phase I/II,Open-Label,Does-Escalation and -Expansion, Safety,Pharmacokinetics and Efficacy Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Nov 15, 2018·Updated Feb 5, 2021

In Brief

A Phase 2 clinical trial evaluating SHR3680 and SHR2554 for Prostate Cancer and Castration-resistant Prostate Cancer. Terminated early, enrolled 9 participants across 1 site.

Signals

Trial was terminated early

Detailed Summary

The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Castration-resistant Prostate Cancer
CountriesChina
Collaborators--

Timeline

Phase 2TerminatedFinished
20192020202120222023202420252026
First PostedNov 15, 2018
Enrollment StartNov 20, 2018
Primary CompletionSep 30, 2019
Study CompletionDec 8, 2020
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 7.6 years ago

Interventions

SHR3680drug

Tablet. Specifications of 80mg

SHR2554drug

Tablet. Specifications of 50mg and 200mg